Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

PloS One
Hiroki WatanabeCAPITAL-RCT investigators

Abstract

Despite its recommendation by the current guidelines, the role of long-term oral beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST-segment elevation myocardial infarction (STEMI) patients without heart failure, left ventricular dysfunction or ventricular arrhythmia who underwent primary percutaneous coronary intervention (PCI). In a multi-center, open-label, randomized controlled trial, STEMI patients with successful primary PCI within 24 hours from the onset and with left ventricular ejection fraction (LVEF) ≥40% were randomly assigned in a 1-to-1 fashion either to the carvedilol group or to the no beta-blocker group within 7 days after primary PCI. The primary endpoint is a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome. Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. The carvedilol dose was up-titrated from 3.4±2.1 mg at baseline to 6.3±4.3 mg at 1-year. During median follow-up of 3.9 years with 96.4% follow-up, the cumulative 3-year incidences of both the primary endpoint and any cor...Continue Reading

Associated Clinical Trials

References

Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Mar 26, 1982·JAMA : the Journal of the American Medical Association
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Apr 12, 2001·The New England Journal of Medicine·P W SerruysUNKNOWN Arterial Revascularization Therapies Study Group
May 3, 2007·JAMA : the Journal of the American Medical Association·Keith A A FoxUNKNOWN GRACE Investigators
Jun 3, 2009·Annals of Internal Medicine·Finlay A McAlisterPaul W Armstrong
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Oct 4, 2012·JAMA : the Journal of the American Medical Association·Sripal BangaloreUNKNOWN REACH Registry Investigators
Oct 2, 2014·Circulation. Cardiovascular Quality and Outcomes·Sripal BangaloreA Michael Lincoff
Dec 3, 2014·Journal of the American College of Cardiology·Frants PedersenErik Jørgensen
Sep 26, 2015·Journal of the American College of Cardiology·Jeffrey J GoldbergerUNKNOWN OBTAIN Investigators
Jan 12, 2017·Circulation. Cardiovascular Quality and Outcomes·Yugo YamashitaUNKNOWN CREDO-Kyoto AMI Registry Investigators
Jun 3, 2017·Journal of the American College of Cardiology·Tatendashe B DondoChris P Gale

❮ Previous
Next ❯

Citations

Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sanam SafiChristian Gluud
Jul 11, 2020·Journal of Hypertension·Costas ThomopoulosGiuseppe Mancia
Aug 21, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Troels Yndigegn, Tomas Jernberg
Jan 16, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Neiko Ozasa, Takeshi Kimura
Feb 24, 2021·The American Journal of Cardiology·Ghaith ZaatariUNKNOWN Outcomes of Beta-blocker Therapy After myocardial INfarction (OBTAIN) Investigators
Mar 31, 2021·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Mari AminoYuji Ikari
Nov 6, 2021·The Cochrane Database of Systematic Reviews·Sanam SafiJanus C Jakobsen

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01155635

Software Mentioned

JMP
SAS

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.